NeutriSci, Scientus Pharma in R&D pact for medical cannabinoid


NeutriSci International (OTCQB:NRXCF; TSX-V:NU; FRANKFURT:1N9) and Scientus Pharma have entered into a major R&D memorandum of understanding to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for existing retail distribution networks across Canada. 

The core ingredients in NeutriSci’s products have significant anti-oxidant properties and health benefits. Scientus Pharma will conduct research, initially funded by NeutriSci, on NeutriSci’s products and their components in combination with various cannabinoids. 

Both companies will have rights for further product development and testing, including potentially preclinical and clinical trials, which may be co-funded. 

"This Scientus Pharma partnership helps position us at the forefront of developing new and innovative cannabinoid based medical products in Canada,” NeutriSci president, Glen Rehman, said in a statement. 

Scientus Pharma, along with its existing partnerships, is sure to be a dominant player in the cannabis space in Canada, he added. “By leveraging both parties existing partnerships, we will be positioned to offer the national retail consumer a safe, effective, dose-controlled product that completes our ‘plant to blood stream’ strategy.” 

Har Grover, chairman of Scientus, said NeutriSci has had success innovating with its neuenergy product and the brand has good presence in several health and wellness settings. “Pterostilbene and related compounds present interesting targets for further research and we are looking forward to this collaboration,” he added.